search
Back to results

Leap Motion Controller on the Functionality of Upper Limbs in Parkinson's Disease

Primary Purpose

Parkinson Disease, Upper Extremity Dysfunction, Therapy-Related MDS

Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Leap Motion Controller
Conventional Physiotherapy
Sponsored by
Federal University of Health Science of Porto Alegre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring Parkinson Disease, Upper Extremity Disfunction, Therapy-Related MDS

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Parkinson's disease diagnostic;
  • Classified as I-III on the Hoehn & Yahr motor staging scale;
  • Are over 18 years old (above this, without age restriction).
  • Residents in the city of Porto Alegre / RS.
  • Have signed an informed consent form.

Exclusion Criteria:

  • Do not show the understanding of the games on the first day of familiarization;
  • Have a cerebral pacemaker implant;
  • Have recent injuries or limitations that make the MMSS impossible.
  • Do not perform / abstain from two appointments out of the 16 proposed in the intervention protocol, regardless of the group that will be allocated.

Sites / Locations

  • Philipe Souza Correa

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Leap Motion Controller

Conventional Physiotherapy

Arm Description

Intervention Group: which will receive treatment with Leap Motion Controller

Control Group: who will receive treatment with conventional physiotherapy.

Outcomes

Primary Outcome Measures

Test TEMPA (Test d'Évaluation des Membres Supérieurs de Personnes Agées)
It is an instrument that serves to assess the degree of disability of the MMSS. It presents a manual on how to manage it, the necessary measures to make the box and where to dispose of each specific material of the tasks. The materials required for administering the test are as follows: 100 gram coffee pot, 1000 milliliter water jar, coffee spoon, cup, water glass, medicine bottle and 10 placebo capsules, white envelopes, seal, pencil , card game, coins (R $ 1, R $ 0.25, R $ 0.50, R $ 0.10), small glass jar (7 cm (cm) in diameter and 5 cm in height), small objects (toothpick, nut, safety pin, 2.5 cm diameter button and nail), piece of non-slip material and sheets for recording scores (MICHAELSEN et al., 2008). The test consists of performing bilateral and unilateral tasks, of the upper limbs.

Secondary Outcome Measures

Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The updated MDS-UPDRS scale comprises four parts: Part I, the impact of non-motor aspects of daily life, part II, motor aspects of daily life, part III, motor assessment and part IV that corresponds to motor complications. However, only part II - motor aspects of daily life will be applied, which is designed to be a self-administered questionnaire, but can be reviewed by the researcher to ensure its clear and complete completion. And part III - motor evaluation, in which it has instructions for the evaluator to provide or demonstrate to the individual and is completed by the evaluator. A higher score corresponds to a corresponding worse state.

Full Information

First Posted
July 21, 2020
Last Updated
September 15, 2023
Sponsor
Federal University of Health Science of Porto Alegre
search

1. Study Identification

Unique Protocol Identification Number
NCT04796246
Brief Title
Leap Motion Controller on the Functionality of Upper Limbs in Parkinson's Disease
Official Title
Leap Motion Controller on the Functionality Of Upper Limbs in Parkinson's Disease: A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
January 15, 2022 (Actual)
Primary Completion Date
June 1, 2022 (Actual)
Study Completion Date
August 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federal University of Health Science of Porto Alegre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Is treatment with the Leap Motion Controller device effective for upper limb functionality in individuals with Parkinson's Disease? The present study presents two hypotheses: True hypothesis: There is an improvement in the functionality of MMSS after intervention with virtual reality? Null hypothesis: There is no improvement in the functionality of MMSS after intervention with virtual reality? The proposed work will be characterized as a Randomized Clinical Trial, with evaluators outside the experimental groups (single-blind). The sample will be probabilistic, from individuals diagnosed with Parkinson's disease.
Detailed Description
STUDY METHODOLOGY RESEARCH DESIGN: The proposed work will be characterized as a Randomized Clinical Trial, with evaluators outside the experimental groups (single-blind). The sample will be probabilistic, from individuals diagnosed with Parkinson's disease. TYPE OF STUDY: Randomized Clinical Trial. AREA OF SCOPE: Major area: Health Sciences. Area: Physiotherapy and Occupational Therapy. LOCATION: The place where the entire study will be carried out will be in the home environment of each research participant. PARTICIPANTS: Participants will be recruited from an existing pre-existing list of research conducted on individuals with Parkinson's Disease from the UFCSPA. Individuals who: - are diagnosed with Parkinson's disease; - Classified as I-III on the Hoehn & Yahr motor staging scale; - Are over 18 years old (above this, without age restriction). - Residents in the city of Porto Alegre / RS. - Have signed the informed consent form (Appendix A). Individuals who: - Do not show the understanding of the games on the first day of familiarization; - Have a cerebral pacemaker implant; - Have recent injuries or limitations that make the MMSS impossible. - Do not perform / abstain from two appointments out of the 16 proposed in the intervention protocol, regardless of the group that will be allocated. The study will consist of two groups: intervention group (IG), which will receive treatment with Leap Motion Controller; and the control group (CG), who will receive treatment with conventional physiotherapy. EVALUATION INSTRUMENTS: A participant identification form will be filled out, containing full name, date of birth, gender, address, telephone number, education, diagnosis, time of diagnosis, onset of symptoms (laterality), associated diseases, PD subtype and medicines. Individuals will be assessed for: the motor aspects of experiences and activities of daily living using the TEMPA test and the Unified Assessment Scale for Parkinson's Disease (MDS-UPDRS) part II; Motor Assessment and subtype of the disease, using the MDS-UPDRS scale III; motor staging of PD using the Hoehn & Yahr scale; muscle strength and endurance, using the handgrip dynamometer (TEMPA test); manual dexterity, through the Box and Block test and the Nine Hole Peg test; cognitive issues through the Montreal Cognitive Assessment (MoCA); and quality of life, through the Questionnaire on Parkinson's Disease (PDQ-39). EXPECTED DURATION: The present research project contemplates different objectives, this being a study proposal to be developed during four years. PROCEDURES: The formation of each of the groups will be done through the generation of a random sequence through the tool available at http://www.randomize.com. Therefore, individuals will be divided into two groups: Intervention Group and Control Group. Subsequently, the initial assessment will be made,TEMPA, MDS-UPDRS-II e III, motor staging of the disease (H&Y), Box and Block Test, Nine Hole Peg Test), MoCA and PDQ-39.The IG will carry out a 2-month intervention protocol, with 16 40-minute interventions, twice a week. The CG will perform a conventional physiotherapy protocol for the same period as the IG. Therefore, all groups will receive the same evaluation procedures that will be performed before the intervention (PRE), after the intervention (POST) and, finally, 30 days after the intervention (follow-up). The researchers responsible for the intervention will not be aware of the evaluations carried out and the evaluators will not be aware of the group to which the participant will belong. Both groups will be able to follow their routine activities (physical and / or physical therapy) and all procedures will be performed in the home environment of each research participant. ETHICAL AND LEGAL PROCEDURES The study project in question will be submitted to the Research Ethics Committee of the Federal University of Health Sciences of Porto Alegre (UFCSPA) and will only be applied after due approval. All participants will be informed about the procedures, objectives, justifications, potential risks and benefits of their participation in the study. The research will not present risks to the participant, but if there is any discomfort during any activity, the treatment will be stopped immediately and the necessary measures taken. In addition, all participants must sign the informed consent form and receive a copy of it. The use of any type of image will not identify the participant and will only be used with written consent. The data in the medical record (name, telephone and address) will be used for screening in the identification and contact of individuals and stored in a database that will be accessed only by researchers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Upper Extremity Dysfunction, Therapy-Related MDS
Keywords
Parkinson Disease, Upper Extremity Disfunction, Therapy-Related MDS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
The proposed work will be characterized as a Randomized Clinical Trial, with evaluators outside the experimental groups (single-blind). The sample will be probabilistic, from individuals diagnosed with Parkinson's disease.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Leap Motion Controller
Arm Type
Experimental
Arm Description
Intervention Group: which will receive treatment with Leap Motion Controller
Arm Title
Conventional Physiotherapy
Arm Type
Active Comparator
Arm Description
Control Group: who will receive treatment with conventional physiotherapy.
Intervention Type
Other
Intervention Name(s)
Leap Motion Controller
Intervention Description
Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
Intervention Type
Other
Intervention Name(s)
Conventional Physiotherapy
Intervention Description
The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
Primary Outcome Measure Information:
Title
Test TEMPA (Test d'Évaluation des Membres Supérieurs de Personnes Agées)
Description
It is an instrument that serves to assess the degree of disability of the MMSS. It presents a manual on how to manage it, the necessary measures to make the box and where to dispose of each specific material of the tasks. The materials required for administering the test are as follows: 100 gram coffee pot, 1000 milliliter water jar, coffee spoon, cup, water glass, medicine bottle and 10 placebo capsules, white envelopes, seal, pencil , card game, coins (R $ 1, R $ 0.25, R $ 0.50, R $ 0.10), small glass jar (7 cm (cm) in diameter and 5 cm in height), small objects (toothpick, nut, safety pin, 2.5 cm diameter button and nail), piece of non-slip material and sheets for recording scores (MICHAELSEN et al., 2008). The test consists of performing bilateral and unilateral tasks, of the upper limbs.
Time Frame
Pre and Post Immediate intervention. 30 days after interventions.
Secondary Outcome Measure Information:
Title
Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Description
The updated MDS-UPDRS scale comprises four parts: Part I, the impact of non-motor aspects of daily life, part II, motor aspects of daily life, part III, motor assessment and part IV that corresponds to motor complications. However, only part II - motor aspects of daily life will be applied, which is designed to be a self-administered questionnaire, but can be reviewed by the researcher to ensure its clear and complete completion. And part III - motor evaluation, in which it has instructions for the evaluator to provide or demonstrate to the individual and is completed by the evaluator. A higher score corresponds to a corresponding worse state.
Time Frame
Pre and Post Immediate intervention. 30 days after interventions.
Other Pre-specified Outcome Measures:
Title
Hoehn & Yahr Scale
Description
The Hoehn & Yahr (H&Y) staging scale serves to classify and determine which motor stage of Parkinson's disease the individual is in. It is an easy and quick scale to be applied, which has its modified form, comprising five stages of classification to assess the severity of PD, and is based mainly on the signs and symptoms to assess the individual's level of disability. Individuals rated on the scale between one and three are in stages of mild to moderate disability, while those with stages four and five fall into severe disability.
Time Frame
Pre and Post Immediate intervention. 30 days after interventions.
Title
Box and Block Test
Description
For the application of the manual dexterity test, a wooden box with a length of 53.7 cm is required, with a partition also made of wood higher than the edges of the box, separating it into two compartments of equal dimensions. The blocks also made of wood and in the form of colored cubes (primary colors) of 2.5 cm on a side are 150 in number, divided equally by color. As a prerequisite for the application of the test, a quiet environment is necessary, with the subject being seated in a chair suitable for his / her height. The box must be placed horizontally in front of him so that he has a full view of the area and equipment in question.
Time Frame
Pre and Post Immediate intervention. 30 days after interventions.
Title
Nine Hole Peg Test
Description
The test that assesses manual dexterity consists of nine pins and a plate with nine holes, in which the individual is instructed to take one pin at a time and insert it into the holes contained in the plate and then, later remove the pins and return it. them to the place of origin. The execution time is timed by the researcher.
Time Frame
Pre and Post Immediate intervention. 30 days after interventions.
Title
Montreal Cognitive Assessement - MoCA
Description
The MoCA measures eight cognitive domains, which are scored within a range of 0 to 30 points (higher scores indicating better function): short-term memory (delayed recall, 5 points); visuospatial skills (cube design, 1 point, clock design, 3 points); executive function (trail test, 1 point; phonemic verbal fluency, 1 point; verbal abstraction, 2 points); attention, concentration and working memory (cancellation, 1 point; subtraction, 3 points; digit range, 2 points); language (nomination, 3 points; sentence repetition, 2 points); and orientation in time (3 points) and space (3 points).
Time Frame
Pre and Post Immediate intervention. 30 days after interventions.
Title
Parkinson's Disease Questionnaire - PDQ-39
Description
The Parkinson's Disease questionnaire, PDQ-39, consists of 39 questions covering the topics: mobility, activities of daily living, emotional well-being, social support, body discomfort, stigma, cognition and communication. The individual identifies how often in the last month he found himself in the situations mentioned. The options are never (0 points), rarely (1 point), sometimes (2 points), often (3 points) and always (4 points). Between 0 and 100 the lowest score corresponds to the highest quality of life.
Time Frame
Pre and Post Immediate intervention. 30 days after interventions.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Parkinson's disease diagnostic; Classified as I-III on the Hoehn & Yahr motor staging scale; Are over 18 years old (above this, without age restriction). Residents in the city of Porto Alegre / RS. Have signed an informed consent form. Exclusion Criteria: Do not show the understanding of the games on the first day of familiarization; Have a cerebral pacemaker implant; Have recent injuries or limitations that make the MMSS impossible. Do not perform / abstain from two appointments out of the 16 proposed in the intervention protocol, regardless of the group that will be allocated.
Facility Information:
Facility Name
Philipe Souza Correa
City
Porto Alegre
State/Province
RIO Grande DO SUL
ZIP/Postal Code
55
Country
Brazil

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Leap Motion Controller on the Functionality of Upper Limbs in Parkinson's Disease

We'll reach out to this number within 24 hrs